Clinical trials: Climacteric Symptoms
Menopause, Hot Flashes
Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)
This study will evaluate whether an 8-week course of a standardized herbal extract containing Shatavari and natural bio-enhancer ingredients can reduce menopausal symptoms in post-menopausal women.
- Trial name
- RENEW (NCT07834463)
- Testing
- Shatavari (Asparagus racemosus) Extract
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- India Glycols Ltd
Hot Flashes
A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause
Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes.
- Trial name
- Starlight 3 (NCT06206421)
- Testing
- Fezolinetant
- Where
- 24 sites in Japan
- Volunteers
- 277 people
- Sponsor
- Astellas Pharma Inc
Menopause
The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women
To determine whether treatment with ESTRATEST® Tablets is superior to treatment with esterified estrogens tablets
- Trial name
- NCT00141544
- Testing
- esterified estrogens 1.25 mg and methyltestosterone 2.5 mg, Esterified estrogens 1.25 mg
- Where
- 78 sites in United States
- Volunteers
- 28 people
- Sponsor
- Solvay Pharmaceuticals
Menopause, Postmenopausal Vaginal Atrophy
Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms
This trial is conducted in North America. The purpose of this study is to determine if Vagifem Low Dose is an effective and safe treatment for patients suffering from postmenopausal atrophic vaginitis.
- Trial name
- NCT00108849
- Testing
- estradiol, 10 mcg
- Where
- 57 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Novo Nordisk A/S
Hot Flushes, Vasomotor Symptoms
A Study of MF101 in Postmenopausal Women
This phase 3a study is designed to assess the safety and efficacy of MF101 on the frequency of moderate to severe hot flushes in postmenopausal women.
- Trial name
- HERBA (NCT00906308)
- Testing
- MF101 5 g/day, MF101 10 g/day
- Where
- 50 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Bionovo
Menopause, Hot Flashes
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of…
- Conditions
- Menopause, Hot Flashes, Sleep Disorders
- Trial name
- NCT00256685
- Testing
- DVS-233 SR
- Volunteers
- 568 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Female Urogenital Diseases, Urinary Incontinence
Clinical Trial of "Magic Gyno" Laser Device
The aim of this prospective study is investigation of efficiency and safety of medical device "Magic Gyno" in accordance with the stated purpose.
- Conditions
- Female Urogenital Diseases, Urinary Incontinence, Prolapse Genital, Menopausal Syndrome
- Trial name
- NCT05463081
- Testing
- Laser treatment, Blood test, Clinical urine test
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- MeLSyTech, Ltd
Vaginal Atrophy, Sexual Dysfunction
Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause
This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 nm lasers for treatment of symptoms of Genitourinary Syndrome of Menopause.
- Conditions
- Vaginal Atrophy, Sexual Dysfunction, Dyspareunia, Vaginal Dryness
- Trial name
- NCT03178825
- Testing
- Hybrid Fractional Laser
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sciton
Atrophy, Vaginal Diseases
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity
The purpose of this study is to determine the safety and efficacy of ospemifene in postmenopausal women experiencing moderate to severe vaginal dryness and vaginal pain associated with sexual activity.
- Trial name
- NCT00729469
- Testing
- Ospemifene 60 mg
- Volunteers
- 919 people
- Sponsor
- Shionogi
Vasomotor Symptoms (VMS) Associated With Menopause
An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States
Menopause is a natural stage in a woman's life happening between ages 45 and 55. It is often associated with disruptive symptoms like hot flashes and sleep disturbances that can affect up to 8 out of 10 women and make daily life…
- Trial name
- RELIEF (NCT07490431)
- Testing
- No intervention
- Volunteers
- 2,400 people
- Sponsor
- Bayer
Hot Flashes
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
This study was for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Skylight 2 (NCT04003142)
- Testing
- Fezolinetant
- Where
- 93 sites in United States, Canada and 5 more
- Volunteers
- 501 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Climacteric Symptoms
China Cimicifuga Trial of Climacteric Complaint Control
This study is designed to determine whether an extract of Cimicifuga Foetida L. is safe and efficacious to relieve the climacteric symptoms of Chinese women
- Trial name
- CCCCC (NCT00622986)
- Testing
- an extract of Cimicifuga Foetida L.
- Where
- 13 sites in China
- Volunteers
- 288 people
- Sponsor
- Shandong Luye Pharmaceutical Co., Ltd.
Heavy Uterine Bleeding, Uterine Fibroids
Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
The purpose of this proof-of-concept study is to assess the safety and effectiveness of elagolix versus placebo to reduce uterine bleeding associated with uterine fibroids, and to reduce fibroid volume and uterine volume in…
- Trial name
- NCT01441635
- Testing
- Elagolix, Estradiol/Norethindrone acetate (E2/NETA), Estradiol
- Volunteers
- 271 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Menopause, Dietary Supplements
Effects of a New Botanical Extracts Combination on Quality of Life in Menopausal Spanish Women
This study was designed to evaluate the beneficial effects and safety of a standardised botanical extract combination containing soy isoflavone extract, grains of paradise seed dry extract and pomegranate skin dry extract on…
- Conditions
- Menopause, Dietary Supplements, Quality of Life
- Trial name
- NCT04381026
- Testing
- Botanical dry extracts combination
- Where
- Spain
- Volunteers
- 57 people
- Sponsor
- Nektium Pharma SL
Hot Flashes
Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women
Depomed's Gabapentin Extended Release is an investigational, extended release formulation of Gabapentin that is being studied for the treatment of Hot Flashes/Hot Flushes in postmenopausal women
- Trial name
- Breeze3 (NCT01080300)
- Testing
- Gabapentin Extended Release
- Where
- 66 sites in United States
- Volunteers
- 600 people
- Sponsor
- Depomed
Healthy
A Randomized, Double Blind, Placebo Controlled, Clinical Study to Examine the Benefits of an Oral Product in Panelists With Menopausal Symptoms Including Vasomotor Symptoms (VMS).
Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Study with a Run-in Baseline, Daily Diary Log, and Validated Questionnaires (Greene GCS) with Oral Dietary Supplement
- Trial name
- NCT07033013
- Testing
- Dietary Supplement with actives
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Olly, PBC
Menopause, Hot Flashes
The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women
The objective of this study is to evaluate the safety and efficacy of extended-release oxybutynin chloride for the treatment of vasomotor symptoms, also known as hot flashes, in healthy naturally postmenopausal women.
- Trial name
- NCT00990886
- Testing
- Oxybutynin chloride
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.
The goal of this clinical trial is to improve the management of Genitourinary syndrome of menopause (GSM) to preliminary assess safety and effectivity of a novel hormone-free mucosa composition (XCMIM20m) applied topically to the…
- Conditions
- Vulvar Atrophy, Vulvovaginal Signs and Symptoms, Genitourinary Syndrome of Menopause, Quality of Life
- Trial name
- STOPGSMP (NCT06962345)
- Testing
- Hormone-free vulvovaginal gel with the tested composition XCMIM20m
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Mucosa Innovations, S.L.
Menopause
Satavari and Ashoka for Menopause (SAM) Study
This 12-week randomized, placebo-controlled clinical trial will evaluate the efficacy and safety of a daily oral supplement containing Ashoka Bark and Shatavari in women experiencing menopausal symptoms.
- Trial name
- SAM (NCT07861295)
- Testing
- Ashoka Bark and Shatavari
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vidya USA Corporation
Menopause, Vulvovaginal Atrophy
TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy
The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 μg in treating moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of treatment, and to estimate the effect size and…
- Conditions
- Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
- Trial name
- NCT02449902
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- TherapeuticsMD